Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors

The purpose of this study is to determine if the experimental treatment with poly-ADP ribose polymerase (PARP) inhibitor, ACE-86225106 is safe, tolerable and has anti-cancer activity in adult patients with advanced solid tumors.

Trial Details

NCT ID
NCT06380660
Phase
PHASE1 / PHASE2
Sponsor
Acerand Therapeutics (Shanghai) Limited
Status
RECRUITING
Cancer Type
Castration-Resistant (CRPC) Prostate Cancer
Interventions
  • ACE-86225106 tablet
Locations (sample)
  • Chongqing, Chongqing Municipality, China|29.56026,106.55771
  • Fuzhou, Fujian, China|26.06139,119.30611
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Anyang, Henan, China|36.096,114.38278
  • Zhengzhou, Henan, China|34.75778,113.64861

Key Eligibility Criteria

  • Provide written informed consent;
  • Advanced solid tumors, difficult to treat or intolerant to standard treatment, suitable for investigational treatment;
  • Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
  • Has a life expectancy of at least 3 months;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Castration-Resistant (CRPC) Prostate Cancer Trials on Trialify →